Ikwo Oboho1, Alison G Abraham, Lorie Benning, Kathryn Anastos, Anjali Sharma, Mary Young, Pamela Burian, Monica Gandhi, Mardge Cohen, Lynda Szczech. 1. *Department of Medicine, Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, MD †Department of Epidemiology, The Johns Hopkins University, Bloomberg School of Public Health, Baltimore, MD ‡Departments of Medicine, Epidemiology and Population Health, Montefiore Medical Center, Bronx, NY §Department of Medicine, State University of New York Health Science Center, Brooklyn, NY ‖Department of Medicine, Georgetown University Medical Center, Washington, DC ¶Department of Medicine, Division of Hematology, University of Southern California, Los Angeles, CA #Department of Medicine, University of California-San Francisco, San Francisco, CA **Department of Medicine, Cook County Hospital, Chicago, IL ††Department of Pharmacovigilance, Pharmaceutical Product Development, Morrisville, NC.
Abstract
BACKGROUND: Tenofovir (TDF) has been associated with renal tubular injury. Biomarkers that signal early tubular dysfunction are needed because creatinine rise lags behind TDF-associated kidney dysfunction. We examined several urinary biomarkers to determine if rises accompanying TDF initiation preceded creatinine changes. METHODS: Three urinary biomarkers of tubular impairment--neutrophil gelatinase-associated lipocalin (NGAL), N-acetyl-β-D-glucosaminidase (NAG), and β-2-microglobulin (β2MG)--were measured across 3 time points (one pre-TDF visit and 2 post-TDF visits) in 132 HIV-positive women from the Women's Interagency HIV Study. Women initiating highly active antiretroviral therapy (HAART) containing TDF were propensity score matched to women initiating HAART without TDF and women not on HAART. RESULTS: There were no differences between groups for NGAL or NAG, but β2MG was 19 times more likely to be elevated among TDF users at the second post-TDF visit compared with non-TDF users at the pre-TDF visit (P < 0.01). History of proteinuria was associated with elevated NGAL (P < 0.01). Factors associated with elevated NAG were glomerular filtration rate <60 mL/minute, history of proteinuria, hepatitis C (P < 0.01 for all), and diabetes mellitus (P = 0.05). Factors associated with increased odds of elevated β2MG were HIV RNA >100,000 copies/mL, hepatitis C, boosted protease inhibitor use, and glomerular filtration rate <60 mL/minute (P ≤ 0.01 for all). CONCLUSIONS: β2MG levels are elevated in women on TDF, indicating probable early renal dysfunction. Biomarker elevation is additionally associated with baseline chronic kidney disease, uncontrolled viremia, and boosted protease inhibitor use. Future studies are needed to explore urinary biomarker thresholds in identifying treated HIV-infected individuals at risk for renal dysfunction.
BACKGROUND:Tenofovir (TDF) has been associated with renal tubular injury. Biomarkers that signal early tubular dysfunction are needed because creatinine rise lags behind TDF-associated kidney dysfunction. We examined several urinary biomarkers to determine if rises accompanying TDF initiation preceded creatinine changes. METHODS: Three urinary biomarkers of tubular impairment--neutrophil gelatinase-associated lipocalin (NGAL), N-acetyl-β-D-glucosaminidase (NAG), and β-2-microglobulin (β2MG)--were measured across 3 time points (one pre-TDF visit and 2 post-TDF visits) in 132 HIV-positive women from the Women's Interagency HIV Study. Women initiating highly active antiretroviral therapy (HAART) containing TDF were propensity score matched to women initiating HAART without TDF and women not on HAART. RESULTS: There were no differences between groups for NGAL or NAG, but β2MG was 19 times more likely to be elevated among TDF users at the second post-TDF visit compared with non-TDF users at the pre-TDF visit (P < 0.01). History of proteinuria was associated with elevated NGAL (P < 0.01). Factors associated with elevated NAG were glomerular filtration rate <60 mL/minute, history of proteinuria, hepatitis C (P < 0.01 for all), and diabetes mellitus (P = 0.05). Factors associated with increased odds of elevated β2MG were HIV RNA >100,000 copies/mL, hepatitis C, boosted protease inhibitor use, and glomerular filtration rate <60 mL/minute (P ≤ 0.01 for all). CONCLUSIONS: β2MG levels are elevated in women on TDF, indicating probable early renal dysfunction. Biomarker elevation is additionally associated with baseline chronic kidney disease, uncontrolled viremia, and boosted protease inhibitor use. Future studies are needed to explore urinary biomarker thresholds in identifying treated HIV-infected individuals at risk for renal dysfunction.
Authors: Pankaj Seth; Dale Porter; Jaana Lahti-Domenici; Yan Geng; Andrea Richardson; Kornelia Polyak Journal: Cancer Res Date: 2002-08-15 Impact factor: 12.701
Authors: Kerry M Sheets; Mohamed G Atta; Derek M Fine; Katie Zook; Allison M Mcfall; Michelle M Estrella; George J Schwartz; Gregory M Lucas Journal: J Acquir Immune Defic Syndr Date: 2017-05-01 Impact factor: 3.731
Authors: William R Zhang; Rebecca Scherzer; Michelle M Estrella; Simon B Ascher; Anthony Muiru; Vasantha Jotwani; Carl Grunfeld; Chirag R Parikh; Deborah Gustafson; Seble Kassaye; Anjali Sharma; Mardge Cohen; Phyllis C Tien; Derek K Ng; Frank J Palella; Mallory D Witt; Ken Ho; Michael G Shlipak Journal: AIDS Date: 2019-03-15 Impact factor: 4.177
Authors: Lisa Hamzah; Amanda Samarawickrama; Lucy Campbell; Matthew Pope; Keith Burling; Martin Fisher; Yvonne Gilleece; Karen Walker-Bone; Frank A Post Journal: AIDS Date: 2015-09-10 Impact factor: 4.177
Authors: Sanjiv M Baxi; Rebecca Scherzer; Vasantha Jotwani; Michelle M Estrella; Alison G Abraham; Chirag R Parikh; Michael R Bennett; Mardge H Cohen; Marek J Nowicki; Deborah R Gustafson; Anjali Sharma; Mary A Young; Michael G Shlipak Journal: J Acquir Immune Defic Syndr Date: 2017-04-15 Impact factor: 3.731
Authors: Tino Salome; Ivan Kasamba; Billy Nsubuga Mayanja; Patrick Kazooba; Jackson Were; Pontiano Kaleebu; Paula Munderi Journal: AIDS Res Ther Date: 2016-08-30 Impact factor: 2.250